E
Spruce Biosciences, Inc. SPRB
$0.1298 -$0.0101-7.22% NASDAQ
Recommendation
Prev Close
$0.1298
Volume
534,726
Avg Vol (90D)
932,069
Market Cap
$5.48M
Dividend & Yield
--
52-Week Range
$0.11 - $0.87
P/E (TTM)
--
EPS (TTM)
-$1.28
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Spruce Biosciences, Inc. (NASDAQ:SPRB) Q1 2023 Earnings Call Transcript
4/17/2025 - Insider Monkey
Spruce Biosciences, Inc. (NASDAQ:SPRB) Short Interest Down 48.7% in March
4/17/2025 - Ticker Report
Royal Bank of Canada Has Lowered Expectations for Spruce Biosciences (NASDAQ:SPRB) Stock Price
4/16/2025 - Ticker Report
Spruce Biosciences (NASDAQ:SPRB) Posts Earnings Results, Misses Estimates By $0.37 EPS
4/16/2025 - Ticker Report
With BioMarin deal, Spruce Biosciences hits reset on rare-disease drug
4/15/2025 - Bizjournals.com - Health Care News
Spruce Biosciences, Inc. (SPRB) Corporate Update Conference Call (Transcript)
4/15/2025 - Seeking Alpha: Transcripts
Spruce Biosciences, Inc. (SPRB) Corporate Update Conference Call (Transcript)
4/15/2025 - SeekingAlpha
Spruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for ...
4/15/2025 - GuruFocus
Spruce Biosciences (SPRB) Acquires New Therapy for Rare Disease Treatment SPRB Stock News
4/15/2025 - GuruFocus
Spruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for ...
4/15/2025 - GuruFocus
Spruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
4/15/2025 - Business Wire
spruce smartens pipeline deal biomarin asset plans 2026 approval filing
4/15/2025 - FierceBiotech.com - Biotech
Invivyd, Inc. (IVVD) Reports Q4 Loss, Tops Revenue Estimates
3/20/2025 - Zacks Investment Research
Spruce Biosciences, Inc. (NASDAQ:SPRB) Given Consensus Rating of "Hold" by Brokerages
1/25/2025 - Ticker Report
Spruce Biosciences Appoints Interim Chief Medical Officer
12/27/2024 - TipRanks Financial Blog
Spruce Biosciences, Inc. (NASDAQ:SPRB) Receives Consensus Recommendation of and#8220;Hold" from Analysts
12/26/2024 - Ticker Report
HC Wainwright Reaffirms Neutral Rating for Spruce Biosciences (NASDAQ:SPRB)
12/18/2024 - Ticker Report
Spruce Biosciences (NASDAQ:SPRB) Earns and#8220;Sector Perform" Rating from Royal Bank of Canada
12/14/2024 - Ticker Report
Spruce Biosciences (NASDAQ:SPRB) Cut to Hold at Citizens Jmp
12/14/2024 - Ticker Report
Spruce Biosciences (SPRB) Upgraded to Buy: Here's Why
12/13/2024 - Zacks Investment Research
JMP Securities Reaffirms Market Perform Rating for Spruce Biosciences (NASDAQ:SPRB)
12/13/2024 - Ticker Report
Penny Stock Spruce Biosciences Winds Down Tildacerfont Studies For Rare Genetic Disorder
12/11/2024 - Benzinga
Spruce Biosciences just downgraded at Oppenheimer, here's why
12/11/2024 - The Fly
Spruce Biosciences Downgraded to Hold Amid Unmet Clinical Trial Endpoints and Strategic Reevaluation
12/11/2024 - TipRanks Financial Blog
Income Statement
Total Revenue (TTM)
$4.91M
EBITDA (TTM)
-$56.11M
EBIT (TTM)
-$56.15M
Net Income (TTM)
-$53.04M
Balance Sheet
Total Assets (Q)
$45.21M
Total Debt (Q)
$2.77M
Total Liabilities (Q)
$16.39M
Book Value Per Share (Q)
$0.6825
Cash Flow
Cash from Operations (TTM)
-$55.96M
Cash from Investing (TTM)
--
Cash from Financing (TTM)
-$1.62M
Net Change in Cash (TTM)
-$57.59M
Filings
Filing Date
Tuesday, April 15, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of Aug 11 and 15 (est)
Price History
Loading...
Beta
1.78
7-Day Total Return
5.53%
30-Day Total Return
-61.27%
60-Day Total Return
-64.55%
90-Day Total Return
-66.13%
Year to Date Total Return
-69.05%
1-Year Total Return
-81.46%
2-Year Total Return
-93.76%
3-Year Total Return
-93.17%
5-Year Total Return
--
52-week Low
Apr 17, 2025 - $0.11
52-week High
May 09, 2024 - $0.87
Valuation
Market Cap
$5.48M - Nano Cap
Enterprise Value
-$30.51M
Price/Sales (TTM)
1.10
Price/Book (Q)
0.19
Dividends and Shares
Shares Outstanding
41.50M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
sprucebio.com
Phone Number
415 655 4168
Address
611 Gateway Boulevard
South San Francisco, CA 94080
Country
United States
Year Founded
2014
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a... more
NASDAQ 04/25/2025 4:00PM Eastern Quotes delayed